可切除非小细胞肺癌的快速进展:一篇叙述性综述
本叙述性综述总结可切除早期非小细胞肺癌(NSCLC)近期多项改变标准治疗的高关注度临床试验,涉及辅助奥希替尼、新辅助纳武利尤单抗联合化疗及辅助阿替利珠单抗或帕博利珠单抗,并讨论这些结果在临床实践中的应用问题与挑战。
要点
- 辅助奥希替尼3年治疗显著改善EGFR突变可切除NSCLC的DFS和OS,但治疗结束后DFS获益减弱。
- 辅助阿替利珠单抗或帕博利珠单抗可考虑用于术后化疗后约1年,仅PD-L1≥50%患者中阿替利珠单抗显示OS获益。
- 新辅助纳武利尤单抗联合化疗为可切除IB-IIIA期NSCLC带来强EFS获益,但围手术期免疫治疗的最佳模式仍存争议。
核心结论
- 可切除NSCLC领域进展迅速,产生了识别最佳患者和在竞争性新标准间优先排序的实际挑战。
- 部分情况下实际管理需要临床判断并与患者讨论以弥补前瞻性数据的空白。
- 在超出已有数据进行外推时应谨慎。
研究设计与样本
- 叙述性综述,总结可切除早期NSCLC近期改变标准治疗的高关注度临床试验。
主要发现
- 辅助奥希替尼3年治疗与DFS和OS均显著改善相关,但治疗结束后DFS获益减弱,提示更长疗程治疗的潜在价值。
- 其他基因组异常的高效靶向治疗作为辅助治疗有 compelling 理由但目前无数据。
- 辅助阿替利珠单抗或帕博利珠单抗通常在术后化疗后给药1年,是适当的考虑,但仅肿瘤PD-L1水平为50%的患者中阿替利珠单抗显示了OS获益。
- 新辅助纳武利尤单抗联合化疗为可切除IB至IIIA期NSCLC提供强EFS获益、更短的治疗间隔以及影像学和病理学反馈。
- 新辅助化学免疫治疗提高的肿瘤缩小率提示,可切除性标准可能有望在对新辅助化学免疫治疗良好应答的预期下被重新定义。
临床怎么用
- 辅助奥希替尼3年治疗可用于具有EGFR基因组异常的可切除NSCLC患者。
- 辅助阿替利珠单抗或帕博利珠单抗通常在术后化疗后给药1年,是适当的考虑,但仅PD-L1为50%的患者中阿替利珠单抗显示了OS获益。
- 新辅助纳武利尤单抗联合化疗可用于可切除IB至IIIA期NSCLC,提供强EFS获益、更短治疗间隔及影像学和病理学反馈。
- 近期围手术期免疫治疗随机临床试验同时术前联合化疗和术后给药,突显了既往化学免疫治疗后辅助免疫治疗价值的争议。
- 部分情况下实际管理需要临床判断并与患者讨论以弥补前瞻性数据的空白,超出已有数据外推时应谨慎。
局限性
- 其他基因组异常的高效靶向治疗作为辅助治疗有 compelling 理由但目前无数据。
- 仅肿瘤PD-L1水平为50%的患者中阿替利珠单抗显示了OS获益。
- 近期围手术期免疫治疗随机临床试验突显了既往化学免疫治疗后辅助免疫治疗价值的争议。
- 部分情况下实际管理需要临床判断并与患者讨论以弥补前瞻性数据的空白。
- 在超出已有数据进行外推时应谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A series of high-profile clinical trials for patients with resectable early-stage non-small cell lung cancer (NSCLC) have recently changed the standard of care in this setting. Specifically, studies have demonstrated statistically and clinically significant improvements in efficacy with the targeted therapy for adjuvant osimertinib in patients with resected NSCLC harboring an epidermal growth factor receptor (EGFR) genomic abnormality (GA), whereas trials with chemotherapy combined with nivolumab in the neoadjuvant setting and others testing atezolizumab or pembrolizumab as adjuvant therapy have all demonstrated improvements in event-free survival (EFS) (for neoadjuvant therapy) or disease-free survival (DFS) (for adjuvant therapy). These trials introduce many open questions about how to apply these findings in clinical practice. OBSERVATIONS: Treatment with adjuvant osimertinib for 3 years was associated with significant improvement in both DFS and overall survival (OS), but the erosion of the DFS benefit after the duration of treatment ends suggests a potential value for more longitudinal treatment. The potential value of highly effective targeted therapies as adjuvant therapy for other GAs has a compelling rationale but no data at this time. Adjuvant atezolizumab or pembrolizumab, generally administered for 1 year after postoperative chemotherapy, are appropriate considerations, but only atezolizumab for patients with tumor programmed death-ligand 1 (PD-L1) levels of 50% has demonstrated a benefit in OS. Neoadjuvant chemotherapy with nivolumab offers a strong EFS benefit, a shorter interval of treatment, and radiographic and pathologic feedback for patients with resectable stage IB to IIIA NSCLC, although very recent randomized clinical trials of perioperative immunotherapy both combined with chemotherapy preoperatively and administered postoperatively highlight the debatable value of adjuvant immunotherapy after prior chemoimmunotherapy. Improved tumor shrinkage rates with neoadjuvant chemoimmunotherapy suggest the possibility that criteria for resectability may potentially be redefined in anticipation of a good response to neoadjuvant chemoimmunotherapy. CONCLUSIONS AND RELEVANCE: Developments in resectable NSCLC have arrived so rapidly that they have also created practical challenges of identifying optimal patients and prioritizing options among these new competing standards. In some cases, practical management requires clinical judgment and discussion with the patient to cover the gaps in prospective data. Caution should be exerted when extrapolating beyond the available data.
引用
- West HJ, Kim JY. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review. JAMA Oncol. 2024. PMID: 38153722. doi:10.1001/jamaoncol.2023.5276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。